Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Quinapril hydrochloride
Drug ID BADD_D01891
Description Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers.[A184844] Quinapril was granted FDA approval on 19 November 1991.[L8420] A combination tablet with [hydrochlorothiazide] was also approved on 28 December 1999.[L8423]
Indications and Usage Quinapril is indicated for the treatment of hypertension and as an adjunct therapy in the treatment of heart failure.[L8420] Quinapril in combination with hydrochlorothiazide is indicated for the treatment of hypertension.[L8423]
Marketing Status approved; investigational
ATC Code C09AA06
DrugBank ID DB00881
KEGG ID D00459
MeSH ID D000077583
PubChem ID 54891
TTD Drug ID D0I7SZ
NDC Product Code 65862-368; 63187-874; 65862-620; 63827-1009; 63629-7934; 65862-617; 65862-619; 17404-0015; 0071-0530; 0071-0527; 0071-0532; 65862-618; 0071-0535; 15308-0500
UNII 33067B3N2M
Synonyms Quinapril | 2-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid | Accupril | CI 906 | CI-906 | Quinapril Hydrochloride | PD 109452-2 | PD 109452 2 | PD 1094522 | PD-109,452-2 | PD 109,452 2
Chemical Information
Molecular Formula C25H31ClN2O5
CAS Registry Number 82586-55-8
SMILES CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2CC3=CC=CC=C3CC2C(=O)O.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Agranulocytosis01.02.03.001--Not Available
Alopecia23.02.02.001--
Amblyopia06.02.01.001--Not Available
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Angina pectoris02.02.02.002; 24.04.04.002--
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Arrhythmia02.03.02.001--Not Available
Arthralgia15.01.02.001--
Asthenia08.01.01.001--Not Available
Back pain15.03.04.005--
Blood creatine increased13.13.01.001--Not Available
Blood creatinine increased13.13.01.004--
Blood urea increased13.13.01.006--Not Available
Cardiac failure02.05.01.001--
Cardiogenic shock24.06.02.006; 02.05.01.003--Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.011--Not Available
Constipation07.02.02.001--
Cough22.02.03.001--
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis exfoliative23.03.07.001; 10.01.01.004--
Dermatomyositis10.04.04.027; 23.03.02.001; 15.05.01.002--Not Available
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Dry mouth07.06.01.002--
Dry throat22.12.03.005; 07.06.01.005--Not Available
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages